← Back to Screener
Akebia Therapeutics, Inc. (AKBA)
Price$1.35
Favorite Metrics
Price vs S&P 500 (26W)-49.60%
Price vs S&P 500 (4W)1.82%
Market Capitalization$401.82M
All Metrics
P/CF (Annual)5.91x
Book Value / Share (Quarterly)$0.12
P/TBV (Annual)3.91x
Indicated Dividend (Annual)$0.00
Revenue Growth (3Y)-6.88%
Cash Flow / Share (Quarterly)$0.23
Price vs S&P 500 (YTD)-6.37%
Gross Margin (TTM)82.83%
Net Profit Margin (TTM)-2.26%
EPS (TTM)$-0.02
10-Day Avg Trading Volume2.04M
EPS Excl Extra (TTM)$-0.02
Revenue Growth (5Y)-4.32%
EPS (Annual)$-0.02
ROI (Annual)-2.36%
Gross Margin (Annual)82.91%
Net Profit Margin (5Y Avg)-47.54%
Cash / Share (Quarterly)$0.70
Revenue Growth QoQ (YoY)23.93%
ROA (Last FY)-1.42%
Revenue Growth TTM (YoY)47.46%
EBITD / Share (TTM)$0.08
ROE (5Y Avg)-487.05%
Operating Margin (TTM)9.95%
Cash Flow / Share (Annual)$0.23
P/B Ratio12.32x
P/B Ratio (Quarterly)13.10x
Net Income / Employee (Annual)$-0
EV / Revenue (TTM)1.74x
Net Interest Coverage (TTM)0.85x
ROA (TTM)-1.53%
EV / EBITDA (TTM)20.07x
EPS Incl Extra (Annual)$-0.02
Current Ratio (Annual)1.55x
Quick Ratio (Quarterly)1.42x
3-Month Avg Trading Volume3.01M
52-Week Price Return-15.30%
EV / Free Cash Flow (Annual)6.85x
Revenue / Employee (TTM)$1
Tangible BV / Share (Quarterly)$0.12
P/S Ratio (Annual)1.70x
Asset Turnover (Annual)0.63x
52-Week High$4.08
Operating Margin (5Y Avg)-39.76%
EPS Excl Extra (Annual)$-0.02
CapEx CAGR (5Y)90.83%
26-Week Price Return-45.61%
Quick Ratio (Annual)1.42x
13-Week Price Return10.71%
Total Debt / Equity (Annual)5.94x
Current Ratio (Quarterly)1.55x
Enterprise Value$410.545
Revenue / Share Growth (5Y)-15.46%
Asset Turnover (TTM)0.68x
Book Value / Share Growth (5Y)-53.14%
Revenue / Employee (Annual)$1
Inventory Turnover (Annual)2.53x
Pretax Margin (Annual)-1.58%
Cash / Share (Annual)$0.70
3-Month Return Std Dev64.56%
Gross Margin (5Y Avg)77.94%
Net Income / Employee (TTM)$-0
ROE (Last FY)-16.39%
Net Interest Coverage (Annual)0.85x
EPS Basic Excl Extra (Annual)$-0.02
P/FCF (TTM)5.47x
Receivables Turnover (TTM)5.80x
EV / Free Cash Flow (TTM)6.85x
Total Debt / Equity (Quarterly)5.94x
EPS Incl Extra (TTM)$-0.02
Receivables Turnover (Annual)5.80x
ROI (TTM)-2.41%
P/S Ratio (TTM)1.70x
Pretax Margin (5Y Avg)-47.40%
Revenue / Share (Annual)$0.92
Tangible BV / Share (Annual)$0.70
Forward P/E380.50x
Price vs S&P 500 (52W)-45.13%
Year-to-Date Return-3.73%
5-Day Price Return9.93%
EPS Normalized (Annual)$-0.02
ROA (5Y Avg)-26.82%
Net Profit Margin (Annual)-2.26%
Month-to-Date Return11.51%
Cash Flow / Share (TTM)$-0.13
EBITD / Share (Annual)$0.08
Operating Margin (Annual)9.95%
LT Debt / Equity (Annual)5.40x
P/CF (TTM)5.91x
ROI (5Y Avg)-94.04%
LT Debt / Equity (Quarterly)5.40x
EPS Basic Excl Extra (TTM)$-0.02
P/TBV (Quarterly)25.01x
P/B Ratio (Annual)13.10x
Inventory Turnover (TTM)2.55x
Pretax Margin (TTM)-1.58%
Book Value / Share (Annual)$0.12
Price vs S&P 500 (13W)10.03%
Beta0.46x
P/FCF (Annual)6.71x
Revenue / Share (TTM)$0.89
ROE (TTM)-16.70%
52-Week Low$1.14
Analyst Recommendations
Jan 2026
Feb 2026
Mar 2026
Apr 2026
4.36
4.36
4.36
4.36
Industry Peers — Pharmaceuticals(308)
| Symbol | P/S Ratio (TTM) | Revenue Growth TTM (YoY) | Gross Margin (TTM) | EPS Growth (5Y) | Price |
|---|---|---|---|---|---|
AKBAAkebia Therapeutics, Inc. | 1.70x | 47.46% | 82.83% | — | $1.35 |
LLYEli Lilly & Co. | 13.08x | 44.70% | 83.04% | 27.59% | $903.99 |
JNJJohnson & Johnson | 5.94x | 7.87% | 67.95% | 14.90% | $234.54 |
ABBVABBVIE INC. | 6.04x | 8.57% | 71.62% | -2.88% | $208.99 |
MRKMerck & Co., Inc. | 4.41x | 1.31% | 78.55% | 21.23% | $115.46 |
AZNAstraZeneca PLC | 5.28x | 8.63% | 81.31% | 21.88% | $200.47 |
NVSNovartis AG | 4.98x | 8.91% | 75.82% | 15.26% | $149.73 |
NVONovo-Nordisk A/S | 3.62x | 6.43% | 80.98% | 20.66% | $40.93 |
ABTAbbott Laboratories | 3.66x | 6.59% | 56.50% | 8.20% | $95.47 |
PFEPfizer Inc. | 2.47x | -1.64% | 75.81% | -3.51% | $27.22 |
BMYBristol-Myers Squibb Co. | 2.47x | -0.22% | 72.63% | — | $58.96 |
About
Akebia Therapeutics is a biopharmaceutical company specializing in chronic kidney disease treatments. Its marketed products include Auryxia for serum phosphorus control and iron deficiency anemia in CKD patients in the US, and Vafseo for CKD-related anemia in Japan. The company is advancing HIF-PH inhibitors in preclinical development.